More Videos
SPECIAL REPORT
MOST SHARED
- Tiger Woods Released From Hospital After Accident: Report
- 8 Retailers that Gain During the Holidays
- Get Paid Six Figures to Wear a T-Shirt?
- Dubai Spooks Investors But May Bring Buying Opportunity
- Finding the Holiday's Best Buys
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Longer Lines, Fuller Carts This Black Friday
- Global Selloff From Dubai Woes Shows Signs of Winding Down
- The Good Entrepreneur Winner
- Banks Play Down Dubai Exposure, Investors Still Wary
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Global Selloff From Dubai Woes Shows Signs of Winding Down
- Dubai Stock Selloff May Bring Buying Opportunity
- Tiger Woods Out of Hospital After Accident
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Get Paid Six Figures to Wear a T-Shirt?
- The World's Biggest Debtor Nations
- Five Tips for Buying a Foreclosed Home
- Slideshow: Fantasy Christmas Gifts 2009
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
But apparently Roche, which trades on the Swiss stock exchange and only over-the-counter in the U.S., said just enough to generate some enthusiasm.
DNA [DNA
Loading...
()
]shares are rallying, but they're still staying well below the $89 mark that Roche has already offered and that Genentech has said was too little. In their earnings press release and on their conference call this morning, Roche officials refused to give any specifics. They'd only say they remain "totally committed" to the Genentech offer and wouldn't make any comments or answer any questions about a "negotiated agreement" or its ability to finance the deal. Unlike the Genentech earnings conference call where at least a couple analysts tried to pry a nugget out of DNA officials, the analysts on the Roche call completely avoided the topic after the new CEO said at the outset that he and his colleagues wouldn't have anything more to say.
So many analysts, investors and reporters dialed into the Roche call this morning after it had started that one company official later repeated for the benefit of the latecomers that it isn't going to show its hand. Something some analysts and investors were banking on would force Roche to come back with a much higher offer didn't pan out Sunday night when Genentech announced the test of Avastin as an add-on drug for colon cancer will continue through the end. At least a couple of analysts were speculating the clinical trial might be stopped after a sneak peek at the data they thought might show the drug is working so well that there'd be no need to keep going. That didn't happen. Some believe if or when Avastin is approved for that use that it could add hundreds of millions of dollars in additional annual revenue.
Despite the higher cost of borrowing, the decline in the value of the Swiss franc and the increase in the value of the dollar that have occurred since Roche first came forward, the company apparently still has the wherewithal and the good credit to do the more expensive deal. What do you think?
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes